Tag Archives: #AdComm

FDA Adds New AdComm to Address Genetic Metabolic Diseases

Back in December 2023, FDA announced intention in the Federal Register and in a press release to form a new FDA Advisory Committee to be called the Genetic Metabolic Diseases Advisory Committee (GeMDAC). As noted in a recent posting here, … Continue reading

Posted in Advisory Committee Prepapartion | Tagged , , , | Comments Off on FDA Adds New AdComm to Address Genetic Metabolic Diseases

The Year in AdComms – A Look Back at 2023

For those working closely with the development of new medicines for FDA approval, it can be informative respecting the future to look back at recent activity and take note of any potential changes from years past. Now, with no more … Continue reading

Posted in Advisory Committee Prepapartion | Tagged , , , , | Comments Off on The Year in AdComms – A Look Back at 2023

Drug Approvals and FDA AdComms in 2023

Having passed the mid-year point, it is always an interesting exercise to take stock of where we stand with respect to the approval of new medicines. Overall, when considering the volume of activity, things would seem to be looking up … Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Tagged , , , | Comments Off on Drug Approvals and FDA AdComms in 2023

Thumbs Up, Thumbs Down – Minimizing Votes in AdComms

The FDA Commissioner has said he would like to limit votes in AdComms – is that really a good idea? Continue reading

Posted in Advisory Committee Prepapartion, FDA Policy | Tagged , , | Comments Off on Thumbs Up, Thumbs Down – Minimizing Votes in AdComms

Emerging from Emergency – Two COVID-Related Developments This Week

Two announcements occurred this week, both of note and connected only by the fact that they are emblematic of the slow metamorphosis from a COVID emergency world to a post-COVID emergency one. Emergency Ends – First, the Biden Administration announced … Continue reading

Posted in FDA Image, FDA Policy | Tagged , , , , | Comments Off on Emerging from Emergency – Two COVID-Related Developments This Week